New agents in chronic myelogenous leukemia

Jorge Cortes, Francis Giles

Research output: Contribution to journalArticle

Abstract

Multiple new agents are currently being developed in chronic myelogenous leukemia (CML). Most of these agents are now being investigated in patients who have developed resistance to imatinib. Their mechanisms of action are diverse and many may be synergistic with imatinib. These agents will be used soon in different combinations, most likely including imatinib, with the hope of obtaining a complete blockade of the intracellular pathways that are triggered by Bcr-Abl. If this is successful, complete eradication of disease may become a reality for the majority of patients with CML.

Original languageEnglish (US)
Pages (from-to)501-512
Number of pages12
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume1
Issue number4
DOIs
StatePublished - Nov 1 2003
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Disease Eradication
Imatinib Mesylate

Keywords

  • Bcr-abl
  • Chemotherapy
  • Chronic myelogenous leukemia
  • Imatinib
  • Intracellular pathways
  • New agents

ASJC Scopus subject areas

  • Oncology

Cite this

New agents in chronic myelogenous leukemia. / Cortes, Jorge; Giles, Francis.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 1, No. 4, 01.11.2003, p. 501-512.

Research output: Contribution to journalArticle

@article{aa45767d5f194b7ea165e8cb624f510e,
title = "New agents in chronic myelogenous leukemia",
abstract = "Multiple new agents are currently being developed in chronic myelogenous leukemia (CML). Most of these agents are now being investigated in patients who have developed resistance to imatinib. Their mechanisms of action are diverse and many may be synergistic with imatinib. These agents will be used soon in different combinations, most likely including imatinib, with the hope of obtaining a complete blockade of the intracellular pathways that are triggered by Bcr-Abl. If this is successful, complete eradication of disease may become a reality for the majority of patients with CML.",
keywords = "Bcr-abl, Chemotherapy, Chronic myelogenous leukemia, Imatinib, Intracellular pathways, New agents",
author = "Jorge Cortes and Francis Giles",
year = "2003",
month = "11",
day = "1",
doi = "10.6004/jnccn.2003.0042",
language = "English (US)",
volume = "1",
pages = "501--512",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "4",

}

TY - JOUR

T1 - New agents in chronic myelogenous leukemia

AU - Cortes, Jorge

AU - Giles, Francis

PY - 2003/11/1

Y1 - 2003/11/1

N2 - Multiple new agents are currently being developed in chronic myelogenous leukemia (CML). Most of these agents are now being investigated in patients who have developed resistance to imatinib. Their mechanisms of action are diverse and many may be synergistic with imatinib. These agents will be used soon in different combinations, most likely including imatinib, with the hope of obtaining a complete blockade of the intracellular pathways that are triggered by Bcr-Abl. If this is successful, complete eradication of disease may become a reality for the majority of patients with CML.

AB - Multiple new agents are currently being developed in chronic myelogenous leukemia (CML). Most of these agents are now being investigated in patients who have developed resistance to imatinib. Their mechanisms of action are diverse and many may be synergistic with imatinib. These agents will be used soon in different combinations, most likely including imatinib, with the hope of obtaining a complete blockade of the intracellular pathways that are triggered by Bcr-Abl. If this is successful, complete eradication of disease may become a reality for the majority of patients with CML.

KW - Bcr-abl

KW - Chemotherapy

KW - Chronic myelogenous leukemia

KW - Imatinib

KW - Intracellular pathways

KW - New agents

UR - http://www.scopus.com/inward/record.url?scp=70349774724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349774724&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2003.0042

DO - 10.6004/jnccn.2003.0042

M3 - Article

C2 - 19774741

AN - SCOPUS:70349774724

VL - 1

SP - 501

EP - 512

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 4

ER -